Loading...
Loading...
TFFP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 125.1K |
| Gross Profit | -125.1K |
| Operating Expense | 4,420.6K |
| Operating I/L | -4,420.6K |
| Other Income/Expense | -77.5K |
| Interest Income | 88.8K |
| Pretax | -4,409.2K |
| Income Tax Expense | -88.8K |
| Net Income/Loss | -4,409.2K |
TFF Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in developing and commercializing drug products using its patented Thin Film Freezing (TFF) technology platform. The company focuses on inhaled dry powder drugs for pulmonary diseases, with lead candidates including TFF Voriconazole Inhalation Powder and TFF Tacrolimus Inhalation Powder, both in Phase II clinical trials. Additionally, the company is developing other dry powder products such as cannabidiol substance for epilepsy syndromes, Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19, Niclosamide Inhalation Powder for tapeworm infections and COVID-19, and other vaccines.
